Overview
- Editors:
-
-
A. Michael Lincoff
-
Experimental Interventional Laboratory, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, USA
Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
-
Eric J. Topol
-
Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, USA
Access this book
Other ways to access
Table of contents (16 chapters)
-
-
Basic Principles
-
-
- Thaddeus R. Tolleson, Robert A. Harrington
Pages 3-20
-
-
- Debbie A. Law, David R. Phillips
Pages 35-66
-
-
Glycoprotein IIb/IIIa Blockade During Coronary Intervention
-
-
-
- Conor O’Shea, James E. Tcheng
Pages 115-126
-
- Mahomed Y. Salame, Spencer B. King III, Nicolas A. Chronos
Pages 127-142
-
- Marcel J. B. M. van den Brand, Maarten L. Simoons
Pages 143-168
-
- A. Michael Lincoff, Eric J. Topol
Pages 169-197
-
Glycoprotein IIb/IIIa Blockade for Acute Ischemic Syndromes
-
Front Matter
Pages 199-199
-
- David J. Moliterno, Harvey D. White
Pages 201-227
-
- Adam B. Greenbaum, Robert A. Harrington, E. Magnus Ohman
Pages 229-249
-
Practical Issues and Future Applications
-
Front Matter
Pages 251-251
-
-
- Neal S. Kleiman, Wojciech Mazur, Nikki Graziadei
Pages 267-285
-
- Dean J. Kereiakes, Christopher P. Cannon
Pages 287-314
-
About this book
In Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, the major investigators working in this rapidly advancing field join together under the aegis of A. Michael Lincoff and Eric J. Topol to provide the first comprehensive overview of the preclinical and clinical development of the glycoprotein IIb/IIIa receptor antagonists. These acknowledged experts elucidate the theoretical basis for the inhibition of platelet aggregation in the treatment of coronary syndromes, present and synthesize evidence for the efficacy of glycoprotein IIb/IIIa blockade in inhibiting ischemic complications of both coronary intervention and acute coronary syndromes, and provide guidelines for the use of this novel class of agents in the clinical management of cardiovascular disease. They also compare the pharmacology and clinical efficacy of the currently available glycoprotein IIb/IIIa receptor inhibitors and speculate about further potential applications of these agents in the treatment of vascular disease.
Written by the scientists and physicians who discovered and characterized this important new class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers the most complete and authoritative review of these powerful new therapeutics available today.
Reviews
"Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease claims to be a "comprehensive, definitive, and detailed overview of the preclinical and clinical development of the class of glycoprotein IIb/IIIa receptor antagonists." It is. For the most part, this book achieves its four goals: elucidating the theoretical basis for platelet inhibition in treatment of coronary syndromes, presenting and synthesizing the evidence for the efficacy of glycoprotein IIb/IIIa blockade in coronary interventions and acute coronary syndromes, providing guidelines for the use of this class of agents, and anticipating future applications...The authors are authorities in their respective areas...Presentations are generally clear and well organized, and chapters are well illustrated with diagrams, graphs, and charts as the material warrants....as a single resource covering virtually the entire spectrum of information related to GPIs, it will be extremely valuable to cardiology interventionists, health care practitioners concerned with management of coronary ischemic syndromes, and formulary committees charged with ensuring cost effective use of these expensive agents."-The Annals of Pharmacotherapy
